Abstract
Introduction
In solid tumors, most patients do not die from primary tumors, but from distant metastases that may develop even years after treatment of the primary tumor. In breast cancer, for example, about one third of axillary node-negative patients develop local or distant metastases during the further course of their disease, even if there was no evidence of tumor spread beyond the breast at the time of the primary diagnosis [1, 2] . Metastases are probably caused by occult hematogenous spreading of tumor cells early during the disease course. Several studies support the hypothesis that minimal residual disease (MRD), or isolated tumor cells (ITCs), in the bone marrow of cancer patients can be regarded as the precursor of clinically manifest distant metastases [3] [4] [5] [6] [7] [8] [9] [10] . Thus, early detection of MRD in bone marrow has the potential for more accurate risk stratification in subsequent therapy decisions or even tailoring of additional conventional or targeted therapies to eradicate these cells before they become overt metastases. This review mainly focuses on the clinical relevance of detecting MRD in the bone marrow of breast cancer patients, because the most comprehensive research has been carried This material is protected by U.S. Copyright law.
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In general, new markers, such as MRD in bone marrow, may serve as prognostic factors, indicating the further course of the disease, or as predictive factors, with regard to expected therapy response. Moreover, new markers themselves may serve as targets for new biological therapies. However, before new markers can be implemented in everyday patient management, they need to fulfill certain quality criteria regarding determination methodology and demonstrate clinical relevance [11] . Next, to have a plausible biological rationale for using the particular marker, its determination method needs to be robust, standardized, and quality-assured. Its clinical impact needs to be validated by independent clinical studies and, finally, the marker must be clinically useful, that is, it must be able to support clinical decision-making independently of existing markers. According to Hayes and colleagues [12] , new markers obtain the highest level of evidence (LOE I) by validation in a prospective clinical trial or a meta-analysis. This paper examines these four major quality criteria for the transfer of new markers into clinical routine in relation to MRD and reviews whether, and in what detail, MRD in bone marrow meets these criteria (Table 1) .
MRD Detection in Bone Marrow: Methodological Considerations
The majority of the studies demonstrating a correlation between MRD and patient prognosis used immunocytochemical detection methods [4] [5] [6] [7] [8] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Using this approach, the presence of extrinsic epithelial cells in the mesenchymal bone marrow compartment can be demonstrated (Fig. 1) . Normal, nondysplastic epithelial cells are not capable of migrating outside their original host organ, except in chronic inflammation after epithelial-mesenchymal transition [32] . Thus, the presence of extrinsic epithelial cells in bone marrow indicates the malignant nature of these cells [33, 34] . However, methodological differences in ITC detection using either immunocytochemical or molecular pathological methods have led to controversial interpretations regarding the clinical relevance of the respective results [35] .
Several studies have shown that ITC detection using monoclonal antibodies is a clinically feasible method [5, 8, 25] . However, caution needs to be exercised with regard to the choice of markers and antibodies. Some antigens, such as epithelial membrane antigen (EMA) or mucin-1, are coexpressed by hematopoietic precursor cells such as erythroblasts. Current data suggest that antibodies directed against these polymorph epithelial mucins (PEMs) label 2%-10% of the mesenchymal mononucleated cells of healthy volunteers [36] . Many studies have therefore used monoclonal antibodies against cytokeratins (CKs), which are major constituents of the epithelial cytoskeleton. These proteins are regularly and abundantly expressed by epithelial cells and their malignant descendents. Anti-CK antibodies have been shown to yield a higher degree of specificity than antibodies directed against PEMs [3, 28, 30] . While illegitimate CK mRNA expression by hematopoietic cells may potentially take place [37] [38] [39] [40] [41] , this problem is not relevant for immunocytochemical methods, because CK antigens are only very rarely detected in these cells [19, 28, 42, 43] . Consequently, false-positive control aspirates may be explained by spurious staining of plasmacytoid cells [32] or may reflect the presence of a yet-undiagnosed malignancy [30] . Further justification for the use of CK as an ITC marker is presented by studies of Klein et al. [44, 45] and Mueller et al. [46] , who identified nuclear characteristics of CK-positive cells that are commonly found in breast carcinoma cells by genetic analysis. Finally, a combination of several antibodies directed against various CK antigens may be used to account for the antigenic heterogeneity of tumor cells [22, 43] . A reliable, quantitative detection assay was established [47] using the proposal of Borgen et al. for a standardized immunocytochemical protocol to be used as a gold standard [48] . This assay, which is known for reproducible sensitivity and specificity [19] , uses the monoclonal anti-CK antibody A45-B/B3 [49] , which detects an epitope present on several CK polypeptides. At least 2 × 10 6 cells per patient need to be screened to render satisfactory sensitivity. Screening can be performed either manually, by bright-field microscopy, or automatically, by an image-analysis scanning system. The latter method may contribute to a superior readout by avoiding cumbersome and fatiguing manual analysis [50] [51] [52] [53] [54] . Previous methodical studies using surrogate model systems (e.g., cell line tumor cells spiked into bone marrow specimens) demonstrated a 95% chance for immunocytochemical detection of a single cancer cell in 2 × 10 6 bone marrow cells [55] . However, the relevance of such studies may be questionable, because it remains unclear how homogeneous tumor cell lines reflect the heterogeneity within patient bone marrow samples. This heterogeneity is a variable that may considerably influence the actual assay sensitivity. Enrichment methods are now available to improve sensitivity and reproducibility of the detection assays. Clinical evaluation of these enrichment methods, however, is still warranted [26, 49, [56] [57] [58] [59] .
In addition to immunocytochemical methods, molecular approaches have been used to detect ITCs. These methods mainly use a polymerase chain reaction (PCR)-mediated amplification of tumor cell DNA or of cDNA generated by reverse transcription of mRNA (RT-PCR) [60] [61] [62] [63] [64] . However, so far, the specificity of RNA-based markers has remained a critical issue due to low-level illegitimate expression of relevant markers in surrounding nonmalignant cells and the fact that distinction between viable and nonviable cells is impossible [65] . With quantitative RT-PCR techniques that enable an estimate of the number of reference gene transcripts in bone marrow samples in relation to the marker gene (e.g., CK 19), a cutoff level can be created to distinguish between malignant and nonmalignant cells [66, 67] .
Flow cytometry has been established for MRD detection in lymphoma and leukemia [68, 69] . However, whether this method bears any advantage over immunocytochemistry for MRD detection in patients with epithelial tumors remains to be shown. In particular, the low number of ITCs present in bone marrow aspirates of early-stage breast cancer patients may severely hamper the flow cytometric approach. The studies published so far comparing flow cytometry with immunocytochemistry show rather divergent results, depending on the specific detection method used [70] [71] [72] [73] . The clinical relevance of flow cytometry for MRD detection in epithelial tumors still remains to be demonstrated and may require the additional use of efficient and reproducible tumor cell-enrichment procedures.
MRD in Solid Tumors
Most epithelial tumors, such as breast cancer, tend to develop bone metastases during disease progression. But even in patients suffering from carcinomas that generally do not metastasize to bone, such as cervical or gastrointestinal carcinomas, ITCs can be detected in the bone marrow (Table 2 ) [34] . In this section, we highlight some of the key findings regarding MRD in solid tumors other than breast cancer.
In approximately 20%-30% of ovarian cancer patients without overt metastatic spread, ITCs can be detected in the bone marrow. Such early dissemination in ovarian cancer seems to be correlated with poor patient outcome, particularly with regard to the development of distant metastases, as shown by one study [74] . Multivariate analysis identified a positive bone marrow finding as an independent prognostic factor for reduced distant disease-free survival (DFS). However, in another study, including 73 patients with earlystage ovarian cancer, detection of tumor cells in the bone marrow and/or blood was not associated with a poor prognosis [75] . This discrepancy may be explained by differ-ences in the study assays (CK versus glycoprotein), length of follow-up, and patient groups studied.
In a series of 130 patients with cervical cancer of the uterus, 29% presented with disseminated tumor cells in their bone marrow at the time of primary diagnosis [76] . The presence of ITCs did not correlate with established prognostic factors, such as tumor stage, histopathologic grading, or invasion of lymph nodes. There was no correlation between bone marrow status at the time of the primary diagnosis and overall survival (OS). However, multivariate analysis revealed the presence of ITCs as a significant, independent risk factor for the subsequent development of distant metastases. In another study, on 24 patients with human papillomavirus-positive cervical carcinoma, 25% had disseminated tumor cells in blood samples and/or bone marrow aspirates. A significant association was found between disseminated tumor cells detected by PCR and local recurrence and survival of the patients [77] .
MRD in bone marrow has also been studied in gastrointestinal carcinomas such as gastric, esophageal, and Abbreviations: CEA, carcinoembryonic antigen; CK, cytokeratin; DDFS, significant correlation between positive bone marrow status and distant disease-free survival; DFS, significant correlation between positive bone marrow status and disease-free survival; HPV, human papillomavirus; ICC, immunocytochemistry; MACS, magnetic-activated cell sorting; OS, significant correlation between positive bone marrow status and overall survival; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; uPA-R, urokinase-type plasminogen activator receptor. colorectal cancers. In colorectal cancer, several studies showed prevalences of ITCs by immunocytochemical techniques ranging from 20%-32% [78] [79] [80] , whereas the detection rate was higher, at 65%, when enrichment techniques or PCR was used [81] [82] [83] [84] . With respect to clinical outcome, ITCs detected by immunocytochemical techniques proved to be an independent prognostic marker in multivariate analyses. In all large studies, the presence of ITCs predicted a shorter distant DFS time than in patients with negative bone marrow status [78] [79] [80] ; Leinung et al. [78] also reported a shorter survival time in patients with ITCs present in the bone marrow. For molecular detection methods, however, a prognostic significance could not be shown, probably due to the small patient numbers in these studies. The correlation between a positive bone marrow finding and established risk factors was rather weak.
In gastroesophageal cancer, a wide range of detection rates of ITCs, from 29%-67%, has been reported. The prognostic relevance of ITCs in bone marrow is still a matter of controversy. The presence of ITCs in bone marrow of patients with gastric cancer was found to be associated with tumor stage [85] and predicted both DFS and OS [86, 87] . Macadam et al. [88] and Thorban et al. [89] confirmed bone marrow micrometastases as an independent prognostic variable for both recurrence and survival by multivariate analysis. However, other studies failed to show a correlation between the presence of CK-positive cells in bone marrow and clinical outcome [90] . Differences in the choice of antibody, staining procedures, and cytological interpretation may partly explain these discrepant results. Therefore, additional markers have been proposed to more reliably identify those patients at high risk for recurrence. In gastric cancer patients, urokinase-type plasminogen activator receptor (uPA-R) expression on ITCs was shown to be a predictor of reduced recurrence-free survival and OS [91] .
Early tumor cell dissemination after complete resection of the primary tumor is frequent in lung cancer and seems to indicate early occult metastatic spread of the disease. Few studies have been published to evaluate MRD in the bone marrow so far, but the incidence of ITCs seems fairly high, ranging from 40%-60% [22, 28, 92, 93] . Furthermore, all studies have shown a prognostic significance of ITCs in the bone marrow at diagnosis. In one series of 139 patients, bone marrow status was a strong predictor for both tumor relapse and tumor-associated death, which could also be confirmed by multivariate analysis [28, 93] . Further prospective clinical trials have underlined the relevance of ITCs in bone marrow as a predictor of poor prognosis and reduced OS in various other epithelial tumor entities, including head and neck [94] [95] [96] , prostate [97] [98] [99] [100] [101] , pancreatic [102] [103] [104] [105] , and renal and bladder [106, 107] cancers, and neuroblastoma [108] [109] [110] [111] [112] [113] [114] .
Prognostic Relevance of MRD in Breast Cancer
In breast cancer, histopathological methods show a very low ITC detection rate in conventional bone marrow biopsies [115] . Thus, this technique was criticized as an inadequate diagnostic tool due to its limited sensitivity. Therefore, immunocytochemical procedures have been used by most research groups, with some more recent studies also publishing RT-PCR results (Table 3 ). The majority of discrepant results can be attributed to substantial methodological discrepancies among trials. In particular, differences in sensitivity and specificity of the applied techniques and antibodies, as well as the number of analyzed bone marrow cells, methods of specimen collection and preparation, and the use of enrichment techniques may influence detection rates and prognostic relevance. Whereas older studies investigating bone marrow biopsies show ITCs in 1%-17% of patients, detection rates in aspiration specimens are considerably higher. Using immunocytochemical techniques based on monoclonal antibodies directed against epithelial cell antigens, the incidence of ITCs in patients without overt metastases lies in the range of 13%-43%. In comparison with immunocytochemical techniques, some more recent publications have shown a higher incidence of CK-positive cells by RT-PCR, ranging from 26%-71%. However, sufficient methodological validation has so far only been provided for immunocytochemical detection methods using CK antibodies [18, 47] , with a false-positive rate as low as 1% [3].
Single-Center Studies in Breast Cancer
As the presence of ITCs in bone marrow only partially correlates with established prognostic factors at the time of primary diagnosis, it could serve as a parameter providing prognostic information independent of conventional clinical and pathological criteria. Whereas most studies substantiate a prognostic relevance of ITCs at primary diagnosis [4, 6-10, 30, 31, 116-120], some authors were not able to find an association between bone marrow status and recurrence-free survival or OS [15, 66, 71, [121] [122] [123] [124] [125] [126] . However, most trials lacking a significant correlation with survival were early studies, investigating bone marrow biopsies using glycolipid or mucin antibodies. Moreover, patient numbers in those studies were rather small [33] . An early meta-analysis comprising 2,494 patients from 20 studies was not able to confirm bone marrow status as an independent predictor of recurrence-free survival and OS [127] . Even though that meta-analysis included a substantial number of patients, it comprised individual studies with rather divergent detection methods, thus making comparison of the studies extremely difficult.
In more recent studies, comprising substantial patient numbers and sufficient follow-up, an increasing prognostic relevance of ITCs in bone marrow has been established. Using an anti-EMA antibody, Mansi et al. found a significant prognostic influence of bone marrow status at the time of primary diagnosis on the later manifestation of distant metastases and on OS after a median follow-up of 12.5 years. However, in contrast to tumor size and nodal status, ITCs were not confirmed as an independent prognostic factor on multivariate analysis [10] . In a large patient cohort of 727 patients, Diel et al. found correlations between bone marrow status and distant DFS and OS after a median follow-up of 36 months. The independent prognostic impact of ITCs on survival was even superior to that of lymph node status, tumor stage, and grade [5] . Furthermore, all four recent prospective trials, comprising a total of 2,316 patients, confirmed by multivariate analysis that the presence of CK-positive cells in the bone marrow predicts poor prognosis independently of conventional prognostic factors [3, 6, 7, 31]. 
Pooled Analysis in Breast Cancer
A recent pooled analysis analyzed data of 4,703 patients with stage I, II, or III breast cancer [126] . The analysis evaluated patient outcome over a 10-year follow-up period (median, 5.2 years) using a multivariable piecewise Cox regression model. All patients were free of distant metastases at the time of primary surgery; 90% had pT1 and pT2 tumors; 58% were node-negative; and 70% had received adjuvant therapy. The prevalence of isolated tumor cells was 30.6% and significantly associated with larger tumor size, higher grade, lymph node metastasis and hormonereceptor negative tumors (each, p < .001). The presence of isolated tumor cells was a significant prognostic parameter for poor overall and breast cancer-specific as well as disease-free and metastasis-free survival during the entire 10-year observation period (univariate mortality ratios, 2.15, 2.44, 2.13 and 2.33, respectively; p < .001). In multivariable analysis, isolated tumor cells outperformed the traditional prognostic variables for poor survival. In univariate subgroup analysis, breast cancer-specific mortality among patients with isolated tumor cells was significantly elevated (p < .001) for those on either adjuvant endocrine (mortality ratio, 3.22) or cytotoxic therapy alone (mortality ratio, 2.32) and for patients who had pT1N0 disease and did not receive adjuvant systemic therapy (mortality ratio, 3.65) The present analysis meets the criteria for level I evidence for the prognostic value of isolated tumor cells. The authors propose its consideration for routine breast cancer staging and risk stratification in future clinical trials.
Therapy Monitoring and Potential Clinical Impact of MRD in Breast Cancer
Current strategies for the detection and characterization of ITCs in the bone marrow of breast cancer patients could allow for improved tumor staging and therapeutic targeting, and for the first time, the possibility of monitoring the efficacy of adjuvant therapy. One of the intriguing opportunities for this marker could be in the monitoring of therapeutic efficacy in the adjuvant setting in the absence of disease measurable by conventional means. In a pilot study, patients with high-risk breast cancer (more than three involved axillary lymph nodes or extensive invasion of cutaneous lymph vessels) receiving a standard taxane-or anthracycline-containing chemotherapy regimen were monitored by bone marrow analysis before and after adjuvant chemotherapy [21] . The overall prevalence of positive bone marrow findings before and after chemotherapy remained essentially unchanged. In addition, the presence of tumor cells after therapy was associated with an extremely poor prognosis and pointed to a heterogeneous response to treatment. In the high-dosage chemotherapy setting, two pilot studies in breast cancer patients receiving either ifosfamide (Ifex ® ; Bristol-Myers Squibb, Princeton, NJ, http:// www.bms.com), carboplatin (Paraplatin ® ; Bristol-Myers Squibb), and epirubicin (Ellence ® ; Pfizer Pharmaceuticals, New York, http://www.pfizer.com) (n = 18) or vinblastine (Velban ® ; Eli Lilly and Company, Indianapolis, http://www. lilly.com), ifosfamide, and carboplatin (n = 10) chemotherapy with autologous stem cell transplantation showed ITCs in 15 (83%) and in three (30%) bone marrow specimens, respectively, obtained after completion of treatment, even though the majority of patients were in complete clinical remission [128] . These findings support the discrepancy between clinical diagnosis and the imminent risk of relapse represented by MRD. This observation may serve as an explanation for treatment failure of high-dosage chemotherapy. The persistence of ITCs even after aggressive conventional systemic therapy shows the need for complementary strategies with proven efficacies and superior specificities for tumor cells, such as cell cycle-independent therapy.
Two more recent studies have examined the prognostic relevance of persistent ITCs in the bone marrow of earlystage breast cancer patients without evidence of recurrence [129] [130] [131] . In one study, bone marrow aspirates of 228 patients were analyzed during the recurrence-free followup at a median interval of 21.3 months after the primary diagnosis of breast cancer stage pT1-pT2, pN0-N3, pM0 [132] . The results, by both univariate and multivariate analyses, demonstrated that MRD was not only detectable for a long period of time, but that its persistence also predicted a significantly increased risk for relapse and cancer-associated death. Patients without evidence of persistent ITCs had a significantly longer OS duration (162.1 months) than patients with positive bone marrow status (98.7 months; p = .0008). In a multivariate Cox regression analysis, adjusting for initial bone marrow status, tumor size, nodal status, and histopathological grade, persistent ITCs were an independent significant predictor for reduced DFS (relative risk [RR], 4.57; p < .0001) and OS (RR, 5.57; p = .002).
In a second trial, Wiedswang et al. confirmed the prognostic relevance of persistent ITCs at 3 years after the primary diagnosis (n = 356) [130] . In that analysis, persistent MRD was found in 15% of patients. After a median follow-up of 66 months, the presence of persistent ITCs was a strong independent prognostic factor for both DFS and OS. In a multivariate analysis, adjusting for initial bone marrow status, axillary lymph node status, tumor size, HER-2/neu overexpression, and vascular invasion, ITC presence at follow-up bone marrow aspiration was associated with an RR of 7.5 (p = .007) for breast cancer-related death.
In addition to therapy monitoring, ITCs may be valuable therapy targets. Since these cells frequently remain nonproJanni, Rack, Lindemann et al. 487 liferative or dormant [133, 134] , cell cycle-independent, antibody-based therapy appears to be a promising therapeutic option. In a pilot study by Braun et al. [20] , a single 500-mg dose of edrecolomab (Panorex ® , GlaxoSmithKline, Philadelphia, http://www.gsk.com) was administered to 10 advanced breast cancer patients. Edrecolomab is directed against the epithelial cell adhesion molecule (EpCAM), which is widely expressed on breast cancer cells. A marked reduction in the pretherapeutic tumor cell load of all patients was seen at a second follow-up bone marrow aspiration within 5-7 days after antibody treatment. In four of the 10 patients, no CKpositive/EpCAM-positive metastatic cells were present after treatment with edrecolomab. Because edrecolomab exhibits a marked antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in ex vivo experiments with serum of treated patients, it is very likely that the observed disappearance of tumor cells from bone marrow was caused by the administered antibody. No immediate alteration of the clinical course of the disease was observed-a fact that is not surprising considering the advanced stage of the study patients. Presumably due to the overwhelming tumor burden, physiological barriers might prevent antibodies from penetrating the tumor mass [135, 136] .
In the adjuvant setting, however, antibodies directed against EpCAM have been shown to be more effective. Among the first studies to test this therapeutic rationale, the pivotal trial of edrecolomab versus placebo in Dukes' C colorectal cancer patients demonstrated that a clinical benefit is achievable in the adjuvant setting [64] . Patients were treated with five sequential doses of edrecolomab directed against EpCAM, which is almost homogeneously expressed in colorectal cancer. In the 7-year follow-up update [137] , the edrecolomab-treated group experienced a 30% lower mortality and incidence of distant metastases than the untreated control group. In contrast, a subsequent phase III trial on 2,761 stage III colon cancer patients reported no benefit in survival by adding edrecolomab to adjuvant chemotherapy. Patients treated with edrecolomab monotherapy in that trial had a lower OS and DFS than patients treated with chemotherapy alone [138] . Despite frequent EpCAM expression in the primary tumors of colon and pancreatic cancer patients, EpCAM-positive ITCs in the bone marrow have been found in only 7% of breast cancer patients in the adjuvant setting; whereas in patients with advanced breast cancer, 68% of tumor cells were EpCAM-positive [139] . Hence, the lower efficacy in some trials might be attributed to inadequate patient selection, and newer agents with better affinity and delivery might offer additional benefits.
Therefore, these data suggest that targeted therapies for selected patient populations, for example, guided by ITC phenotyping, may be among the most promising treatment options in the future. Different techniques, including immunofluorescence double staining (Figs. 2, 3) , fluorescence in situ hybridization, and many others, have been developed to visualize the antigenic profile of ITCs. In cases with distinct molecular targets, specific antibody-based therapies, such as trastuzumab (Herceptin ® ; Genentech, Inc., South San Francisco, CA, http://www.gene.com) [140] , may be most effective. Furthermore, looking at the possibility of extended adjuvant endocrine treatment [141] , detection of persistent ITCs and subsequent hormone receptor analysis could be beneficial. Finally, protein target-independent agents, such as bisphosphonates, have demonstrated therapeutic efficacy in patients with evidence of MRD in the bone marrow [117, 142] .
Conclusions
The recent pooled analysis by the Collaborative Group Bone Marrow Micrometastasis provides the highest level of evidence for the independent prognostic relevance of ITCs in the bone marrow of breast cancer patients at the time of primary diagnosis. MRD detection may help to stratify patients for tailored adjuvant treatment strategies and facilitate adjuvant therapy decisions. Moreover, in view of the data on persistent MRD and the technical advances in phenotyping these cells, the detection and characterization of MRD in breast cancer patients may not only define patient groups at greater risk for relapse, but may also facilitate the rationale for extended or secondary adjuvant treatment.
However, the detection of micrometastatic disease does not seem to be completely ready for prime time yet. One of the major concerns is the lack of a standardized detection technology. Even though several approaches have been made to suggest standardized methodologies, none of these methodologies has yet become established uniformly. The recent pooled analysis, however, provides highly consistent data comprising results obtained by rather diverse detection techniques. Moreover, the evaluation method is either time consuming, when manual detection is used, or depends on expensive automated equipment. Modern molecular approaches to facilitate MRD detection are neither standardized nor clinically validated yet. With regard to the clinical relevance of MRD, there is no doubt that the presence of these cells at the time of primary diagnosis has an independent prognostic value in breast cancer. Prospective randomized clinical trials are needed to show that any intervention in high-risk patients according to their bone marrow status will lead to a superior outcome. Due to the nonproliferating nature of these cells, it is rather unlikely that conventional chemotherapy will be a solution. Thus, a major challenge for future research is the utilization of ITCs for targeted therapy approaches. Until clinically relevant data regarding successful therapy of MRD are available, treatment interventions on the basis of MRD should be performed only within clinical trials.
